Moy Benjamin M, Bertucci Hanna K, Lemma Betelehem, Rivas Orlyn
Department of Medicine Northwestern University Feinberg School of Medicine Chicago Illinois USA.
Clin Case Rep. 2025 Jul 8;13(7):e70611. doi: 10.1002/ccr3.70611. eCollection 2025 Jul.
Regadenoson, a selective adenosine A2A receptor agonist, is widely used as a stress agent for myocardial perfusion imaging. A2A receptor activation has been implicated in migraines due to its pro-nociceptive effects within trigeminal pain pathways. This case report discusses a 67-year-old female with headache, sudden onset unilateral weakness, and paresthesias after undergoing a PET-CT for ischemic evaluation. Subsequent lab and imaging studies were unconcerning for acute stroke or seizure, raising suspicion for hemiplegic migraine given her extensive neurologic history and rapid onset of symptoms. Regadenoson may be associated with hemodynamic instability and lowering of the seizure threshold. Patients should be screened for neurologic risk factors prior to receiving regadenoson to determine if alternate modalities for ischemic evaluation are more suitable.
瑞加腺苷，一种选择性腺苷A2A受体激动剂，被广泛用作心肌灌注成像的应激剂。由于A2A受体激活在三叉神经痛通路中具有促痛觉过敏作用，因此与偏头痛有关。本病例报告讨论了一名67岁女性，在接受PET-CT进行缺血评估后出现头痛、突发单侧无力和感觉异常。随后的实验室和影像学检查排除了急性中风或癫痫，鉴于她广泛的神经病史和症状的快速发作，怀疑为偏瘫性偏头痛。瑞加腺苷可能与血流动力学不稳定和癫痫阈值降低有关。在接受瑞加腺苷治疗前，应筛查患者的神经危险因素，以确定是否更适合采用其他缺血评估方式。
